Pfizer-BioNTech and AstraZeneca reduce Mortality among the Elderly

Researchers in the UK have demonstrated the efficacy of Pfizer-BioNTech and AstraZeneca vaccines against SARS-CoV-2 preventing death among older individuals. The analysis of more than 48,000 individuals, aged 70 years and older, found that COVID-19 cases who had been vaccinated with one dose of Pfizer-BioNTech’s BNT162b2 vaccine were at a 44% reduced risk of death, compared with unvaccinated individuals, while those vaccinated with one dose of AstraZeneca’s ChAdOx1 vaccine were at a 55% reduced risk.

Among individuals aged 80 years and older who had at least 28 days of follow-up data available, 16.1% of unvaccinated individuals died, compared with 9.2% among those vaccinated with one dose of BNT162b2, 11.3% of those vaccinated with one dose of ChAdOx1, and 4.7% of those vaccinated with two doses of BNT162b2. Among those aged 70-79 years with at least 28 days of follow-up data, 4.0% of unvaccinated individuals died, compared with 2.7% of those who received one dose of BNT162b2, 2.1% of those vaccinated with one dose of ChAdOx1, and 0.0% of those vaccinated with two doses of BNT162b. In the elderly aged above 80 years, it was found that the first dose and second dose of BNT162b2 were 80% and 97% effective at preventing mortality respectively.

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here

Ref Link:

https://www.medrxiv.org/content/10.1101/2021.05.14.21257218v1

#Featured